SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI.
Abstract
Background: Although recent large-scale randomized trials have demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors following acute myocardial infarction (AMI) are safe, the mechanisms underlying their potential cardioprotective effects remain poorly understood.
Objectives: The aim of this study was to evaluate the effects of SGLT2 inhibitor therapy on myocardial injury and left ventricular (LV) remodeling in AMI patients undergoing percutaneous coronary intervention (PCI), using cardiac magnetic resonance imaging (CMR).
Methods: In this prospective, open-label, randomized controlled trial, patients ≥18 years of age at high risk for heart failure after successful PCI for AMI were randomly assigned to receive empagliflozin 10 mg once daily or not. The primary endpoint was infarct size (% LV mass) assessed by CMR at 6-month follow-up. The coprimary endpoint was a difference in LV end-systolic volume measured by CMR between baseline and 6 months (ΔLV end-systolic volume).
Results: A total of 200 patients underwent randomization, with 100 assigned to the SGLT2 inhibitor group and 100 assigned to the control group. CMR assessments for 6 months were available for 169 patients (84.0%) of the total study population (89 patients in the SGLT2 inhibitor group and 80 patients in the control group). Compared with control, SGLT2 inhibition did not reduce infarct size (% LV mass) at 6-month follow-up (SGLT2 inhibitor vs control, 12.5% [8.5%-20.9%] vs 12.9% [5.0%-20.7%]; P =…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 200 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.